Accelerate Rare Disease Drug Development in Light of COVID-19 and Other Challenges
An Integrated Patient-Centric Development Plan, When Applied to Rare and Orphan Medicinal Products (Omps), Can Accelerate Time to Market by 12 to 36 Months
Making it Easier for Patients with Rare Respiratory Diseases to Participate in Clinical Trials
